GLP-1 vs Bariatric Surgery Cost

The GLP-1 vs Bariatric Surgery Cost Comparison Calculator is a strategic financial modeling tool designed for corporate benefits managers, Chief Financial Officers, and self-insured employers. It evaluates the total cost of care (TCC) of lifelong pharmaceutical therapy using GLP-1 receptor agonists against the front-loaded capital expenditures of bariatric surgical interventions. By projecting cumulative liabilities over 5-year, 10-year, and 20-year corporate planning horizons, this tool provides the quantitative foundation required to optimize employee healthcare benefit designs and manage specialty drug spend. From a corporate finance perspective, the decision is a classic comparison of capital expenditure (CapEx) versus operational expenditure (OpEx). Bariatric procedures, such as Roux-en-Y gastric bypass and vertical sleeve gastrectomy, represent a significant, one-time upfront cost that includes pre-operative clearances, facility fees, and post-acute follow-ups, with a minor, actuarially predictable risk of revision. Conversely, GLP-1 medications introduce an indefinite, compounding monthly operational cost that carries high volatility due to PBM rebate structures, supply chain constraints, and the clinical reality that patient discontinuation frequently triggers immediate weight regain and a return of associated comorbidities. Ultimately, this calculator helps corporate decision-makers answer a critical business question: At what point does the upfront investment in a surgical Center of Excellence (COE) yield a positive return on investment compared to the ongoing, open-ended liability of specialty pharmacy coverage? By integrating key business variables like employee turnover rates, stop-loss insurance thresholds, and avoided comorbidity costs, organizations can transition from reactive wellness planning to proactive, data-driven healthcare risk management.

Calkulon makes complex calculations simple — built for students and everyday problem-solvers.

1. 1Input the net monthly employer or plan sponsor cost for GLP-1 medications, ensuring this figure is net of PBM rebates, manufacturer discounts, or administrative fees to accurately reflect actual plan liability.
2. 2Select the primary bariatric surgical procedure under consideration, such as Roux-en-Y Gastric Bypass or Vertical Sleeve Gastrectomy, to establish the comparative clinical and financial baseline.
3. 3Enter the fully-burdened contracted surgical rate, incorporating surgeon fees, anesthesiology, facility charges, pre-operative clearances, and the first 90 days of post-operative care.
4. 4Define the plan's specific cost-sharing parameters, including employer-funded percentages, employee deductibles, copays, and any stop-loss reinsurance attachment points that limit corporate liability.
5. 5Establish the corporate planning horizon—typically 5, 10, or 20 years—to align the analysis with long-term capital allocation strategies, employee tenure metrics, and corporate financial goals.
6. 6Analyze the generated cumulative cash flow models and sensitivity tables to identify the exact payback period, break-even month, and long-term cost differences between the two healthcare pathways.
7. 7Optionally model sequential or hybrid clinical scenarios, such as utilizing short-term GLP-1 therapy as a pre-operative bridge to reduce surgical risk, or as a post-operative rescue therapy for weight regain.

• !Failing to adjust the analysis for average employee tenure and turnover rates, which leads to overestimating the long-term savings of bariatric surgery if employees leave the plan before the break-even month is reached.
• !Ignoring the financial impact of stop-loss reinsurance attachment points, which can absorb extreme individual surgical claims or concentrated specialty drug spend, fundamentally changing the employer's net liability.
• !Assuming 100% long-term compliance on GLP-1 medications, which ignores real-world attrition rates where up to 50% of patients discontinue therapy within the first year, resulting in wasted spend and rapid weight regain.